Drug Approval | September 30, 2022
Lupin receives US FDA approval for Mirabegron Extended-Release tablets
Mirabegron Extended-Release Tablets, 25 mg and 50 mg, had estimated annual sales of US $2.4 billion in US
Mirabegron Extended-Release Tablets, 25 mg and 50 mg, had estimated annual sales of US $2.4 billion in US
The combination of Optym, Emmes' ophthalmology certification unit, and Clinical Edge will make the organization a leader in ophthalmic certification and training services
Sildenafil for Oral Suspension (RLD Revatio) had estimated annual sales of US $64 million in the US
India's healthcare system has shown great efficiency not only in providing diagnostic and management facilities but also in minimizing mortality and maximizing recovery
Diclofenac Sodium Topical Solution USP, 2% w/w (RLD Pennsaid) had estimated annual sales of US $484 million in the US
Krsnaa Diagnostics plans to set up Tele-Pathology Reporting Centre in Pune
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
NATCO is the first company in India to have received its registration approval given by Central Insecticide Board & Registration Committee (CIB&RC) for indigenous manufacture of Chlorantraniliprole
Despite the technological advancements, there remains no alternative to blood and one unit of blood can save as many as three lives
The Department of Health and Family Welfare updated the preparedness for transition to licensing of Class-A and Class-B medical devices with effect from 1st October, 2022 under Medical Devices Rules 2017
Subscribe To Our Newsletter & Stay Updated
